Target intelligence / Profile preview

Dyskerin (None)

Target
None
Molecular classification
Enzyme (pseudouridine synthase, TruB family), Ribonucleoprotein (core component of H/ACA small nucleolar ribonucleoprotein complex)
01

Overview

Dyskerin is an essential, evolutionarily conserved enzyme that serves as the catalytic subunit of the H/ACA ribonucleoprotein (RNP) complex. It catalyzes pseudouridylation, the most common post-transcriptional modification of RNA, which stabilizes RNA molecules and regulates processes such as ribosome biogenesis and pre-mRNA splicing. As a core component of the H/ACA RNP, dyskerin guides the modification of ribosomal RNA (rRNA) and small nuclear RNA (snRNA), impacting gene expression and translation efficiency. Dyskerin is also a critical component of the telomerase holoenzyme, where it binds to and stabilizes the telomerase RNA component (TERC/hTR), essential for telomere maintenance. Mutations in the DKC1 gene, which encodes dyskerin, cause X-linked dyskeratosis congenita, a multisystem disorder characterized by bone marrow failure, abnormal skin pigmentation, and predisposition to cancer. Dyskerin’s multifaceted roles in RNA modification and telomere biology make it a molecule of significant interest in both basic biology and disease research, though targeting it therapeutically remains challenging due to its essential cellular functions[1][2][3].

Other names
H/ACA ribonucleoprotein complex subunit 4NAP57CBF5 (in yeast)NOP60B (in Drosophila)pseudouridine synthase 1
02

Mechanism of action

no drugs specifically targeting dyskerin yet; potential therapeutic strategies might aim to restore dyskerin function or stabilize telomerase RNA component in dyskeratosis congenita

03

Biological functions

RNA pseudouridylationribosome biogenesisrRNA processingtelomerase RNA component (TERC) stabilizationtelomere maintenancepre-mRNA splicing regulationregulation of gene expressiontranslation efficiencycell proliferationhematopoiesis
04

Disease associations

X-linked dyskeratosis congenita (bone marrow failure, premature aging)Hoyeraal-Hreidarsson syndromecancer (due to role in telomere maintenance and cell proliferation)
05

Safety considerations

Loss of dyskerin function leads to severe hematopoietic defects and premature aging phenotypestargeting dyskerin could disrupt essential cellular processes, raising significant toxicity concernsspecificity and off-target effects are major therapeutic challenges
06

Biomarkers

TERC (telomerase RNA component) levelstelomere lengthmutations in DKC1 gene

Beyond the preview

Go deeper on Dyskerin (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dyskerin (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call